Ignite Creation Date:
2024-05-06 @ 11:06 AM
Last Modification Date:
2024-10-26 @ 12:40 PM
Study NCT ID:
NCT03433183
Status:
COMPLETED
Last Update Posted:
2023-12-26
First Post:
2018-01-29
Brief Title:
SARC031 MEK Inhibitor Selumetinib AZD6244 in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sponsor:
Sarcoma Alliance for Research through Collaboration
Organization:
Sarcoma Alliance for Research through Collaboration
Organization Data
Organization:
Sarcoma Alliance for Research through Collaboration
Class:
OTHER
Study ID:
SARC031
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
| United States Department of Defense | FED |